LLY
ELI LILLY & CoPrice & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| International incretin analog market growth | 77% | Q1 2026 call | — |
| Lurio share of new patient starts in metastatic risk cancer | 35% | Q1 2026 call | — |
| Mounjaro U.S. type 2 diabetes incretin analog market share gain | 3% | Q1 2026 call | — |
| pertibrutinib worldwide sales growth | 79% | Q1 2026 call | — |
| Self-pay channel share of total Zepbound prescriptions | 45% | Q1 2026 call | — |
| Self-pay channel share of Zepbound new prescriptions | 55% | Q1 2026 call | — |
| U.S. incretin analog obesity market total prescription growth | 80% | Q1 2026 call | — |
| U.S. new patient starts for Atlas | 90% | Q1 2026 call | — |
| U.S. type 2 diabetes incretin analog market total prescription growth | 11% | Q1 2026 call | — |
| Gross margin as a percent of revenue | 82.5% | Q4 2025 | — |
| Non-GAAP effective tax rate non-GAAP | 19.7% | Q4 2025 | — |
| Research and development expenses as a percent of revenue | 20% | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LLY
this stock
ELI LILLY & Co
|
$1.15T | +13.3% | +44.7% | 43.2 | 1.0% |
|
JNJ
Johnson & Johnson
|
$623.71B | +28.0% | +6.0% | 30.0 | 1.1% |
|
ABBV
AbbVie Inc.
|
$441.54B | +11.5% | +8.6% | 123.1 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$308.98B | +21.4% | +1.4% | 35.2 | 1.2% |
|
NVS
Novartis AG
|
$295.03B | +16.0% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LLY | +1.4% | +5.8% | +13.1% | +1.4% | +13.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +1.6% | +5.0% | +5.6% | +1.6% | +4.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.